Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Downregulation of Transcription Factor LRF/ZBTB7A Increases Fetal Hemoglobin Expression in β-Thalassemia/Hemoglobin E Erythroid Cells

Sukanya Chumchuen, MSc, BSc, Tanapat Pornsukjantra, B.Sc., Pinyaphat Khamphikham, PhD, Usanarat Anurathapan, MD, Orapan Sripichai, PhD, Duantida Songdej, Suradej Hongeng, MD

Blood (2019) 134 (Supplement_1): 3549.

https://doi.org/10.1182/blood-2019-126664

Published: 2019

Journal Articles

ZNF802 (JAZF1), a Possible New Therapeutic Target for Treatment of β-Thalassemia

Chokdee Wongborisuth, MSc, Amornrat Tangprasittipap, PhD, Usanarat Anurathapan, MD, Nuankanya Sathirapongsasuti, MD, PhD, Orapan Sripichai, PhD, Duantida Songdej, Suradej Hongeng, MD

Blood (2019) 134 (Supplement_1): 3546.

https://doi.org/10.1182/blood-2019-127678

Published: 2019

Journal Articles

Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar (HGB-204) Study

Janet L. Kwiatkowski, MD MSCE, Alexis A. Thompson, MD MPH, John E.J. Rasko, MBBS, PhD, Suradej Hongeng, MD, Gary J. Schiller, MD, Usanarat Anurathapan, MD, Marina Cavazzana, MD PhD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Manfred Schmidt, PhD, Morris Kletzel, MD MBA, Elliott P. Vichinsky, MD, Briana Deary, Ying Chen, PhD, Alexandria Petrusich, Mark C. Walters, MD

Blood (2019) 134 (Supplement_1): 4628.

https://doi.org/10.1182/blood-2019-125807

Published: 2019

Journal Articles

Haplo-Identical Stem Cell Transpant Is a Feasible and Safe Treatment Option for Patients with Severe Thalassemia

Suradej Hongeng, MD, Usanarat Anurathapan, MD, Samart Pakakasama, MD, Duantida Songdej, Nongnuch Sirachainan, MD, Ampaiwan Chuansumrit, MD, Borje S Andersson, MD PhD

Blood (2018) 132 (Supplement 1): 3448.

https://doi.org/10.1182/blood-2018-99-115459

Published: 2018

Journal Articles

Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar HGB-204 Study

John E.J. Rasko, MBBS, PhD, Alexis A. Thompson, MD MPH, Janet L. Kwiatkowski, MD, Suradej Hongeng, MD, Gary J. Schiller, MD, Usanarat Anurathapan, MD, Marina Cavazzana, MD PhD, P. Joy Ho, MBBS DPhil FRACP FRCPA, Manfred Schmidt, PhD, Morris Kletzel, MD MBA, Philippe Leboulch, MD, Elliott Vichinsky, MD, Briana Deary, Ying Chen, PhD, Mohammed Asmal, MD PhD, Mark C. Walters, MD

Blood (2018) 132 (Supplement 1): 167.

https://doi.org/10.1182/blood-2018-167

Published: 2018

Journal Articles

Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study

Alexis A. Thompson, MD MPH, Janet Kwiatkowski, MD, John Rasko, MBBS, PhD, Suradej Hongeng, MD, Gary J. Schiller, MD, Usanarat Anurathapan, MD, Marina Cavazzana, MD PhD, P. Joy Ho, Christof von Kalle, MD, Morris Kletzel, MD FAAP, MBA, Philippe Leboulch, MD, Elliott Vichinsky, MD, Alexandria Petrusich, Mohammed Asmal, MD PhD, Mark C. Walters, MD

Blood (2016) 128 (22): 1175.

https://doi.org/10.1182/blood.V128.22.1175.1175

Published: 2016

Journal Articles

Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Pre-Transplant Immunosuppression (PTIS) and Post-Transplant Cyclophosphamide (Post-Cy) in Severe Thalassemia: Safe Approach and Excellent Disease Control

Suradej Hongeng, MD, Samart Pakakasama, MD, Usanarat Anurathapan, MD, Borje Andersson, MD PhD

Blood (2014) 124 (21): 2571.

https://doi.org/10.1182/blood.V124.21.2571.2571

Published: 2014

Journal Articles

Outcome of Intramuscular Anti-D In Children with Chronic Immune Thrombocytopenia (ITP) and Severe Thrombocytopenia: A Case-Control Study,

Nongnuch Sirachainan, MD, Usanarat Anurathapan, MD, Ampaiwan Chuansumrit, MD, Duantida Songdej, MD, Pakawan Wongwerawattanakoon, B.Sc., Sakara Hutspardol, MD, Pimpun Kitpoka, MD

Blood (2011) 118 (21): 3285.

https://doi.org/10.1182/blood.V118.21.3285.3285

Published: 2011

Journal Articles

Adenovirus and BK Virus Co-Infection in the Pediatric Recipient of Stem Cell Transplant with CMV Infection.

Suradej Hongeng, MD, Siriorn Watcharananan, MD, Usanarat Anurathapan, MD, Wisutwadee Piyatuctsanawong, Samart Pakakasama, MD, Nongnuch Sirachainan, MD, Sayomporn Sirinavin, MD, Wasan Chantratita, PhD

Blood (2007) 110 (11): 5010.

https://doi.org/10.1182/blood.V110.11.5010.5010

Published: 2007

NARROW

Downregulation of Transcription Factor LRF/ZBTB7A Increases Fetal Hemoglobin Expression in β-Thalassemia/Hemoglobin E Erythroid Cells

ZNF802 (JAZF1), a Possible New Therapeutic Target for Treatment of β-Thalassemia

Long-Term Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia in the Northstar (HGB-204) Study

Haplo-Identical Stem Cell Transpant Is a Feasible and Safe Treatment Option for Patients with Severe Thalassemia

Clinical Outcomes of Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia Following Completion of the Northstar HGB-204 Study

Lentiglobin Gene Therapy for Transfusion-Dependent β-Thalassemia: Update from the Northstar Hgb-204 Phase 1/2 Clinical Study

Haploidentical Hematopoietic Stem Cell Transplantation (Haplo-SCT) with Pre-Transplant Immunosuppression (PTIS) and Post-Transplant Cyclophosphamide (Post-Cy) in Severe Thalassemia: Safe Approach and Excellent Disease Control

Outcome of Intramuscular Anti-D In Children with Chronic Immune Thrombocytopenia (ITP) and Severe Thrombocytopenia: A Case-Control Study,

Adenovirus and BK Virus Co-Infection in the Pediatric Recipient of Stem Cell Transplant with CMV Infection.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only